INTRODUCTION
Breast cancer, one of the most common types of female can cers, is a highly heterogeneous disease that has multiple sub types with distinct clinical outcomes and a high fatality rate globally [1] . In clinic, the status/expression level of hormone receptor including estrogen receptor (ER), progesterone re cep tor (PR), and human EGFlike receptor 2 (HER2) as well as tu mor grade are often used for classification and target ther apy indicators of breast cancers [1, 2] . Although current early detec tion and target therapies based on the measurement of hor mone receptors have remarkably reduced the rate of mor tality from breast cancer, their application is still limited due to insu fficient sensitivity and specificity as well as the invasive, un pleasant and inconvenient nature of diagnostic procedures. To identify unique therapeutic targets, it is necessary to develop predictive and prognostic biomarkers that can be conveniently and reliably used in clinic.
MicroRNAs (miRNAs), a class of naturally occurring, small and noncoding RNA molecules with a length of 19-25 nucleo tides, can specifically regulate gene mRNA expressions at post transcriptional levels [3] . The dysregulation of miRNAs may affect some crucial biological processes of cells leading to tumor development by increasing proliferation, decreasing apoptosis, and enhancing the metastatic potential [3, 4] . Recently, it has been reported that miRNAs expression level/profile is altered in various cancers exhibiting great potential in improving the diagnosis and prognosis of cancer [5] . Notably, it has been documented that certain secreted miRNAs originating from cancer tissues are protected from endogenous RNase by some unknown mechanisms [6] , and thus can be detected in blood and other body fluids [7, 8] . In breast cancer tissues, miRNAs have been shown to function as either oncogenes or tu mor suppressors [9] , and circulating miRNAs may correlate with disease progression, therapeutic responses and patient sur vival [10, 11] , suggesting that the evaluation of miRNAs levels in the blood, either serum or plasma, may be used as non invasive bloodbased biomarkers. Even though many studies have compared changes of miRNAs levels in blood between breast cancer patients and healthy controls in order to map the profiling of miRNAs and identify some specific miRNAs as potential biomarkers in breast cancer [12] , the results are not always consistent due to the differences in study design, such as sample size, patient source and characteristics, and RNA preparation, as well as detection methods or profiling platforms that were used.
In our study, the serum levels of 5 miRNAs including miR 21, miR155, miR125b, miR145, and miR365 that have been indicated as a recurrent presence in breast cancer patients [12, 13] , were compared between breast cancer patients and healthy controls. We found that the serum level of miR21 was significantly higher, while miR155 and miR365 was signifi cantly lower in breast cancer than healthy control, and receiver operating curve (ROC) analyses showed that the combination of miR21/miR155/miR365 led to higher sensitivity and specificity in distinguishing breast cancer from healthy controls, indicating a potential as biomarkers for the diagnosis and monitoring of breast cancer.
METHODS

Patients
Blood samples were collected from 99 patients with breast cancer (range, 31-77 years; mean, 48.95 years) and 21 agemat ched healthy female volunteers (range, 35-59 years; mean, 45.38 years; without current or previous malignancy or inflammatory condition). In addition, the paired blood samples were collected from a 20patient subset both before and 3 weeks after breast cancer surgery. All participants had signed an informed consent to participate in this study. The study was approved by the Ethics Review Board of Harbin Medical University.
All patients' breast cancer was histologically confirmed. The surgical patients' clinicopathological and relevant demographic characteristics were documented in our prospectively main tained breast cancer database. The clinical stage of breast cancer of all patients was classified according to the TNM classification system of the American Joint Committee on Cancer. The number of various groups' breast cancer patients is summarized in Table 1 .
Serum preparation
A 5mL sample of the whole blood was collected in a Vacu tainer Serum Separator Tube (Becton Dickinson, Franklin Lakes, NJ, USA). The blood was left to clot at room temperature for 30 minutes, and then centrifuged at 2,000 rpm for 10 minutes at 4 o C. The resulting serum was collected, aliquoted, and stored at -80 o C.
RNA extraction
Total RNA was extracted from 300 mL of serum using the mirVana PARIS Kit (Ambion, Carlsbad, CA, USA), and finally eluted into 100 mL of preheated (95 o C) Elution Solution ac cording to the manufacturer's protocol. The eluate was then collected and stored at -20 o C. RNA concentration and inte grity were determined using NanoDrop spectrophotometry 
RT and real-time qPCR
The level of miRNAs was quantified in duplicate using quantitative reverse transcription polymerase chain reaction (RTPCR) and human TaqMan MicroRNA Assay Kit (Applied Biosystems, Foster City, CA, USA). The RT reaction was carried out in a 15mL TaqMan MicroRNA Reverse Transcription System containing 5 mL of RNA extract, 0.15 mL of 100mM dNTPs, 1 mL of Multiscribe Reverse Transcriptase (50 U/mL), 1.5 mL of 10 × RT buffer, 0.19 mL of RNase inhibitor (20 U/mL), 1 mL of gene specific primer and 4.16 mL of nucleasefree water. For cDNA synthesis, the above mixtures were incubated at 16 o C for 30
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Statistical analysis
The unpaired ttest, a twotailed MannWhitney test, was used to compare the differential expression of serum miRNAs between breast cancer and normal samples, between family history positive and negative patients, and between the patients with ER (or PR, HER2, p53) positive and negative. In comparison with healthy controls, the miR21 level was remarkably higher in breast cancer patients at any TNM stage (A), miR155 was significantly higher at stages I and II (D), whereas miR365 was significantly lower at stages I and III (E). Data are expressed as mean ± standard deviation. NS, not significant. analysis of variance was used to compare the differential serum miRNAs level between normal and breast cancer patients at different TNM stages. ROCs were generated using logistic regression models, to evaluate the diagnostic performance of various miRNAs and a combination of miRNAs. Area under curve (AUC) was used as the evaluation criteria; the higher AUC, the better diagnostic performance. All analysis was performed using SAS 9.5 (SAS Institute Inc., Cary, NC, USA) and GraphPad Prism ver. 6 (GraphPad Software Inc., La Jolla, CA, USA). The P < 0.05 was considered as significant difference.
RESULTS
Serum miRNAs levels in breast cancer and healthy samples
It is difficult to extract RNA from serum due to its low abun dance. In our experiments, the average concentration of the total RNA from 300 mL of serum was 0.118 mg/mL ranging from 0.042 to 0.208 mg/mL. As compared with normal samples, the level of miR21 and miR155 was significantly higher (miR21: 0.86 ± 0.941 vs. -2.74 ± 1.055, P <0.0001; miR155: -1.24 ± 1.022 vs. -2.01 ± 0.808, P = 0.0005), while miR365 was significantly lower (-0.84 ± 0.873 vs. -0.24 ± 0.317, P < 0.0001) in breast cancer patients' serum. The level of serum miR125b and miR 145 showed no significant difference between breast cancer and normal samples (Fig. 1) .
Effects of family history and TNM stage on serum miRNAs level in breast cancer patients
We compared the serum level of the five miRNAs in breast cancer patients with or without family history. The five miRNAs levels were not significantly different between family history positive and negative patients with breast cancer (Fig. 2) .
The serum levels of miR21, miR125b, miR145, miR155, and miR365 in breast cancer patients at different TNM stages were also evaluated to determine if the serum miRNAs could be de tected in earlystage breast cancer (Fig. 3) . Across 3 stages, the serum levels of miR21, miR125b, miR145, and miR365 showed no marked difference. In comparison to stages I and II, 
Comparison of serum miRNAs levels in various groups of breast cancer patients
We compared the serum levels of miR21, miR125b, miR 145, miR155, and miR365 in various groups of breast cancer patients classified by hormone status including ER, PR, and HER2 as well as p53 (Fig. 4) . We only detected that the serum level of miR145 was significantly higher (-0.46 ± 0.953 vs. -0.66 ± 0.777, P = 0.041) in PRpositive patients as compared with PR negative (Fig. 4C) . Additionally, in breast cancer pa tients, the positivity of miR21, miR155 and miR365 was 58%, 48%, and 59%, respectively. Nevertheless, the positivity of CA 153 and CEA was 33% and 20%, respectively (Fig. 4F) .
Comparison of serum miRNAs levels before and after surgery in breast cancer patients
The serum level of miRNAs was analyzed in the paired pre and postoperative samples from 20 patients with breast cancer. As compared with the preoperative samples, the level of miR 21 and miR155 decreased significantly (miR21: -0.01 ± 1.318 vs. 1.31 ± 1.082, P = 0.0005; miR155: -1.98 ± 0.944 vs. -0.89 ± 0.921, P = 0.0011) in the postoperative samples (Fig. 5) .
ROC curve analysis
ROC curve analysis was performed to evaluate the diagnostic value for the five miRNAs. The AUCs closer to 1 reflect more substantial differences between breast cancer and normal sam ples. ROC curve analysis revealed that the three miRNAs, miR 21, miR155, and miR365, had significantly higher AUCs with values of 0.788, 0.749, and 0.795, respectively (Fig. 6, Table 2 ). At the optimal cutoff value of -0.089, with the values of sensitivity plus specificity considered to be maximal for miR21, the sensitivity and specificity were 66.67% and 88.89%, respectively. At the optimal cutoff value of -1.171 for miR155, the sensitivity and specificity were 100% and 51.02%, respectively. At the optimal cutoff value of -0.4722 for miR365, the sensitivity and specificity were 85.71% and 72.73%, respectively.
We further performed ROC curve analyses for combinations of miR21, miR155, and miR365. Compared to miR21 alone, the combination of miR21/miR365 yielded higher AUC (0.8677 vs. 0.7879, P = 0.0027), and better sensitivity (96.99%) and specificity (66.67%) (Fig. 7A) . A combination of the three miRNs also created higher AUC (0.9184 vs. 0.8134; P = 0.0261), and better sensitivity (85.71%) and specificity (85.72%) (Fig. 7B) .
DISCUSSION
Endocrine treatment is conventionally used for ER + patients, and trastuzumab for HER2 + patients [14, 15] . Although these biomarkers are commonly used in clinic for target therapy and management of breast cancer, there is still room for improve ment, such as early diagnosis of tumor lesions, identification of highrisk patients, development of predictive biomarkers for monitoring progress and therapy effects, etc. By mapping the circulating miRNAs signature and profiling, some miRNAs have been found differentially expressed in breast cancer and normal tissues [16] . Although the clinical application of serum miRNAs as a noninvasive diagnostic strategy is promising, the miRNA signatures should be further investigated and validated for different subtypes of breast cancers. In the current study, we analyzed the serum level of five miRNAs including miR21, miR125b, miR145, miR155, and miR365 in breast cancers and JiGuang Han, et al: Serum miRNAs as breast cancer biomarkers healthy controls, followed by construction of ROC curves to determine the sensitivity and specificity of circulating miRNAs as potential biomarkers for breast cancer. Our results showed that the serum concentrations of miR 21 and miR155 were significantly elevated, while miR365 was significantly downregulated in patients with breast cancer compared with healthy controls (Fig. 1) . MiR21 is involved in regulating the expression of multiple tumor suppressor genes, and plays a crucial role in the occurrence and development of a variety of cancer diseases [17] . In breast cancer, several studies have shown that upregulation of miR21 was detected in both serum and tissues [18] , and that serum miR21 could be used as an noninvasive biomarker for diagnosis and prognosis of breast cancer as well as an indicator for the invasiveness of the tumor [19] . MiR155 plays a role in various physiological and pathological processes, and oversilencing by miR155 may result in apoptotic resistance and thus triggering oncogenic cascades. It has been reported that the amount of both circulating miR 155 in serum and noncirculating miR155 in tissue were elevated in patients with breast cancer [20, 21] . Therefore, miR 21 and miR155 may act as oncogenic factors, and thus may be potential targets for breast cancer therapy. Additionally, we found that miR155 level was remarkably higher at stages I and II compared to stage III in breast cancer patients (Fig. 3) . Similarly, it has been shown that miR7 was associated with breast cancer grades [22] . Reduction of tissue miR365 has been reported in different types of cancers such as hepatocellular carcinoma (HCC) [23] and lung cancer [24] . An in vitro experi ment showed that overexpression of miR365 remarkably sup pressed proliferation and migration capacities of HCC cell [23] . Kodahl et al. [25] also showed that the serum miR365 was downregulated in early stage breast cancer patients. Family history is an important predisposing factor in breast cancer. How ever, we did not find differential expression of the five miRNAs between family history positive and negative breast cancer patients (Fig. 2) .
In this study, the serum abundance of miR125b and miR145 displayed no remarked difference between breast cancer and healthy control (Fig. 1) . Nevertheless, by comparing the miRNAs profile between 61 breast cancers and 10 healthy controls in the Mexican population, it was found that the serum levels of miR 145 and miR125b were significantly higher in patients with breast cancer than healthy controls [26] . The current analysis just found that serum miR145 abundance was significantly higher in PRpositive breast cancer patients compared to the PRnegative (Fig. 4C ), indicating that serum miR145 level may separate the PRpositive subtypes of breast cancer. A previous study also examined the association of miRNAs expression in serum with different tumor hormone status, and they found 7 miRNAs with differential expression for women whose breast cancer differed by HER2 expression [27] . Notably, it was reported that the level of miR145 was downregulated both in the in vitro cultured breast cancer cell lines [28] and in the serum from early stage breast cancer patients [25] . CA153 and CEA are the most widely used circulating biomarkers in moni toring patients with breast cancer. Nevertheless, we found that the positivity of miR21, miR155 and miR365 was higher in comparison with CEA and CA 153 in breast cancer patients (Fig. 4F) . Similarly, serum miR21 and miR30a has a higher sensitivity in diagnosis of breast cancer compared with CEA and CA153 [29, 30] .
The serum level of miR21 and miR155 was further analyzed in 20 patients with breast cancer before surgery and 3 weeks after tumor removal. The abundance of serum miR21 and miR155 was significantly reduced in the postoperative sam ples as compared with the paired preoperative samples (Fig.  5) . Consistently, Sochor et al. [20] found that early breast cancer patients significantly overexpressed several oncogenic miRNAs such as miR155, miR181b, miR19a, and miR24, which dramatically decreased following surgical resection. Kodahl et al. [25] reported that circulating miR3383p, miR223, and miR148a exhibited lower, and miR107 exhibited higher levels postoperatively than the preoperative samples from 24 postmenopausal women with ER + earlystage breast cancer.
These findings suggest that serum oncogenic miRNAs may be potentially used for diagnostic purpose and relapse judgement.
To determine the diagnostic performance of miRNAs for breast cancer, we performed ROC curve analysis, and the AUC was used as the evaluation criteria; the higher AUC, the better diag nostic performance. Our data revealed that the 3 miRNAs miR21, miR155, and miR365 had significantly higher AUC with the values of 0.788, 0.749, and 0.795, respectively (Fig.  6 ), suggesting that we were able to discriminate breast cancer from healthy controls. The sensitivity for the three miRNAs (miR21, miR155, and miR365) was 66.7%, 100%, and 85.7%, respec tively, and the specificity was 88.9%, 51.02%, and 72.7%, respectively (Fig. 6, Table 2 ). It has been reported that a miRNA panel could accurately distinguish cancers from normal subjects [4, 7, 8, 11, 12] . A combination of ROC curve analyses of miR145, miR155, and miR382 exhibited much better sensitivity and specificity than each miRNA alone [30] . In this study, ROC curve was analyzed in a panel of 3 miRNAs (miR21, miR155, and miR365). Our data demonstrate that a combination of miR21 and miR365 yielded a significantly high AUC (0.868), sensitivity (96.97%), and specificity (66.67%). The combination of miR21, miR155, and miR365 further generated much higher AUC (0.918), accompanied by relatively higher sensitivity (85.71) and specificity (85.72) (Fig. 7, Table 2 ). Accordingly, our results implied that a panel of miRNAs (e.g., a combination of miR 21/miR155/miR365) remarkably enhanced the diagnostic performance with high sensitivity and specificity, and thus may provide an improved indicator for breast cancer diagnosis and screening.
Taken together, our study provides evidence that evaluation of serum miRNAs level can be used as biomarkers for diagnosis of breast cancer, and that a combination of miR21/miR155/miR 365 may potentially serve as a sensitive and specific biomarker that enables the differentiation of breast cancer from healthy controls.
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